Clinical Trial Update: A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the safety and efficacy of daratumumab for primary immune thrombocytopenia is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Immune Thrombocytopenia | Phase 2 | Status: ACTIVE_NOT_RECRUITING